Migraine is a debilitating disease that affects 9% of men and 19% of women worldwide with high socio-economic and personal impact. Surveys indicate that migraineurs are among the most dissatisfied with available therapeutic options, predominantly given via oral or injectable routes, citing side effects as the primary complaint. Orally inhaled therapies have the potential to offer faster onset of action with fewer side effects compared to existing therapies, yet development has stalled. Despite emerging therapies such as calcitonin gene-related peptide antagonists, there are still good opportunities for repositioning migraine drugs via the inhaled route.
Keywords: Aerosol drug delivery; CGRP; DHE; DPI; Ketorolac; Loxapinem; MDI; Migraine; Nasal drug delivery; Prochlorperazine; Sumatriptan; Zolmitriptan.
Copyright © 2018 Elsevier B.V. All rights reserved.